Creates a K-beauty pairing for blemish and oil control, with Niacinamide stabilizing barrier lipid production and blocking melanosomes while Zinc PCA fights C. acnes.
Read the passportSource4
Living ingredient passport
징크피씨에이 · 전성분 · Living ingredient passport
A multifunctional zinc salt of L-pyrrolidone carboxylic acid (L-PCA) that regulates sebum production by inhibiting 5-alpha reductase, fights acne-causing C. acnes bacteria, and deeply hydrates the skin as a natural moisturizing factor.
Also called Zinc Pyrrolidone Carboxylate · Zinc L-PCA · Zinc Salt of L-Pyrrolidone Carboxylic Acid
This ingredient page is still early. We're actively researching before it's ready to stand fully on its own — check back as more sections are verified.
Four lines, each compressed from the section it links to. Every line carries the sources of the claim it compresses.
Antimicrobial Action Against C. acnes and Malassezia
See the evidenceserum, toner, or moisturizer step · day and night
See how to use it14 days: Visible reduction in T-zone oiliness, reduced pore congestion, and fewer active inflammatory redness spots.
Source1
See the timelineWhere it sits in the seven-step ladder, and the record's own fields for the habit.
day and night
Filled steps are where Zinc PCA commonly appears. No product is recommended.
Everything here comes from the sources below. None of it is a product recommendation.
One card per pair. Where the partner has its own passport, the name links to it.
Creates a K-beauty pairing for blemish and oil control, with Niacinamide stabilizing barrier lipid production and blocking melanosomes while Zinc PCA fights C. acnes.
Read the passportSource4
Salicylic acid lipophilically exfoliates inside the pore lining while Zinc PCA calms bacterial inflammation.
The record's own timeline. Each step keeps the source of the study it came from.
Instant skin hydration and reduction in surface oiliness and shine.
Visible reduction in T-zone oiliness, reduced pore congestion, and fewer active inflammatory redness spots.
Source1
Everything the record says about suitability, consolidated. Pause-first comes first.
Before you start
Exceptionally well tolerated, but high concentrations or excessive use on dry skin types can cause mild tightness or dryness.
oily skin
acne-prone skin · congested pores · seborrheic dermatitis · scalp oiliness and dandruff
serum, toner, or moisturizer step
Not medical advice · ask your own clinician
Pregnancy. A 2011 dermatology review of skin-care product safety in pregnancy names hydroquinone (high systemic absorption) and tretinoin (evidence controversial) as the actives of concern, and states that most other topical skin-care products act locally and produce minimal systemic absorption; Zinc PCA is not named among the flagged concerns 5. This is general topical-product reasoning rather than an ingredient-specific safety trial. If you are pregnant, ask your doctor before use.
Breastfeeding. Topical application is applied locally with minimal expected systemic absorption; no ingredient-specific breastfeeding safety trial was located. As a general precaution common to topical actives, avoid applying directly to the breast or nipple area, since incidental transfer to a nursing infant has not been studied for this ingredient. If you are breastfeeding, ask your doctor before use.
| Common, and it usually settles | Stop using it |
|---|---|
| A slight, refreshing, non-stinging sensation; helps balance surface oiliness without peeling or redness. | persistent dryness |
| intense skin tightness | |
| localized redness or rash |
A dedicated search of the peer-reviewed literature (PubMed) for Zinc PCA / zinc pyrrolidone carboxylate allergic contact dermatitis, contact allergy, sensitization, and contraindication case reports found none. This is consistent with, though not proven by, the ingredient's own clinical trial record: both verified clinical sources report zero local side effects within their own trial populations 1,4.
Research in progress — check back soon. How we verify
One card per claim. Concentration, form, population and limitation sit with it, always visible.
Inhibits the proliferation of acne-causing Cutibacterium acnes and Malassezia yeast, reducing inflammatory breakouts and seborrheic dermatitis lesions.1
Inhibits UVA-induced production of collagen-degrading matrix metalloproteinase-1 (MMP-1) in dermal fibroblasts and promotes type I collagen synthesis.2
Large-scale, multi-center, randomized double-blind human clinical trials evaluating pure 1.0% Zinc PCA as a standalone leave-on monotherapy (without Niacinamide or piroctone olamine) specifically measuring facial sebum excretion rates and pore size over 12 weeks.
The research packet's headline sebum-regulation claim (5-alpha-reductase inhibition and 28-day in-vivo sebum reduction) rests on a single flagship source whose cited PMID does not correspond to any real paper matching that title or finding -- the cited PMID actually belongs to a different, unrelated in-vitro UVA-photoaging study this record separately cites for a different, unrelated claim. This record does not map that claim, and does not map the mechanism citation, timeline milestone, or FAQ text that depended on it.
Zinc PCA exerts a dual-action mechanism: the zinc ion competitively inhibits 5-alpha reductase, reducing DHT-driven sebaceous oil secretion 3, and disrupts bacterial cell membranes of C. acnes and Malassezia, while the PCA (pyrrolidone carboxylic acid) moiety acts as an essential Natural Moisturizing Factor (NMF) to bind water in the stratum corneum.
Inhibits 5-alpha-reductase, preventing the enzymatic conversion of testosterone to dihydrotestosterone (DHT) at the sebaceous gland, directly slowing oil production.
What that rests on: in-vitro biochemical enzyme assay
Source3
Suppresses UVA-induced AP-1 transcription, blocking MMP-1 collagenase expression and promoting type I collagen synthesis in dermal fibroblasts.
What that rests on: in-vitro human fibroblast cell assay
Source2
| Attribute | Pure Zinc PCA |
|---|---|
| Official INCI | ZINC PCA |
| Where it comes from | Synthetic reaction of vegetable-derived L-PCA with zinc oxide |
| How it is made | Synthesized by reacting vegetable-derived L-pyrrolidone carboxylic acid (produced from beet molasses) with high-purity zinc oxide in water, followed by crystallization and drying to yield a water-soluble white powder. |
Twice-daily application for 60 days in 20 subjects with facial seborrheic dermatitis significantly decreased erythema, scaling, pruritus, and Malassezia-driven inflammation, with an Investigator Global Assessment (IGA) improvement in 90% of patients.
Where it falls shortTested within a multi-active formula containing piroctone olamine and stearyl glycyrrhetinate, meaning Zinc PCA acted as a synergistic co-active rather than a monotherapy.
Source1
Zinc PCA suppressed UVA-induced production of MMP-1 in dermal fibroblasts in a concentration-dependent manner, while simultaneously enhancing type I collagen synthesis and upregulating ascorbic acid transport.
Where it falls shortEvaluated strictly in vitro on cultured human dermal fibroblasts; clinical in-vivo photoaging studies are needed to confirm anti-wrinkle magnitude.
Source2
Zinc ions demonstrated potent inhibition of 5-alpha-reductase activity in human skin homogenates, completely blocking the conversion of testosterone to dihydrotestosterone (DHT) at sufficient concentrations.
Where it falls shortTested in vitro using human skin homogenates rather than intact living stratum corneum, and on zinc salts generically rather than Zinc PCA specifically.
Source3
Adjuvant treatment with topical Nicotinamide and Zinc PCA significantly reduced inflammatory acne lesion counts, stabilized epidermal barrier function, and reduced transepidermal water loss compared to placebo.
Where it falls shortEvaluated as a combination formula with Nicotinamide in moderate acne subjects.
Source4
Large-scale, multi-center, randomized double-blind human clinical trials evaluating pure 1.0% Zinc PCA as a standalone leave-on monotherapy (without Niacinamide or piroctone olamine) specifically measuring facial sebum excretion rates and pore size over 12 weeks.
The isolated quantitative sebum-reduction magnitude of Zinc PCA as a standalone active in commercial formulations remains partially estimated, as clinical trials frequently evaluate it in combination with Niacinamide or antifungal agents.
NeedsA randomized, double-blind, vehicle-controlled trial assessing 1.0% pure Zinc PCA serum vs vehicle on 100 oily, blemish-prone subjects over 12 weeks.
The research packet's headline sebum-regulation claim (5-alpha-reductase inhibition and 28-day in-vivo sebum reduction) rests on a single flagship source whose cited PMID does not correspond to any real paper matching that title or finding -- the cited PMID actually belongs to a different, unrelated in-vitro UVA-photoaging study this record separately cites for a different, unrelated claim. This record does not map that claim, and does not map the mechanism citation, timeline milestone, or FAQ text that depended on it.
This record cannot state that topical Zinc PCA reduces sebum production or inhibits 5-alpha-reductase in a real, verified in-vivo human trial. The 5-alpha-reductase inhibition mechanism is still supported, but only by a real, generic (non-Zinc-PCA-specific) in-vitro enzyme assay on zinc salts.
NeedsAn independent clinical trial of a topical Zinc PCA formulation, at any concentration, that measures sebum excretion rate against a vehicle or placebo control and reports a real, resolvable citation.